OxCD3: Oxford Centre for Drug Delivery Devices
Lead Research Organisation:
University of Oxford
Department Name: Engineering Science
Abstract
The greatest challenge in oncological drug delivery is achieving successful penetration and distribution of the therapeutic agent throughout the tumour: billions of pounds have been spent to date in deploying biochemical approaches in an attempt to solve what is essentially an engineering problem, namely the transport of therapeutics from the blood stream to reach every cancer cell.
OxCD3 will seek to transform both clinical and industry practice in drug delivery by demonstrating the value and feasibility of engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices already in clinical use, for improved tumour uptake and therapeutic outcome. The Programme Grant will enable the creation of a sustainable, world-unique multi-disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a unique training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice.
A unique feature of the Centre is the capability to design both devices and drug delivery vehicles under a single roof. In the first 5 years, under EPSRC funding, up to 3 carefully selected "Device+Drug" exemplars will be manufactured to GMP, ready for Phase I clinical trials, to provide compelling evidence of feasibility to industrial partners and clinicians; in the next 5 years, a private-public partnership will be built to complete clinical trials of these exemplars using therapeutics of strategic significance to the pharmaceutical industry; beyond 10 years, full industrial sponsorship of the OXCD3 is anticipated, which will focus on addressing next-generation challenges in drug delivery (beyond cancer) in partnership with industry and clinicians. The transformative aim over 50 years is to position the UK as the world leader for multi-disciplinary drug delivery development, complementing its existing position as a drug discovery leader, from design to manufacture and clinical trials.
OxCD3 will seek to transform both clinical and industry practice in drug delivery by demonstrating the value and feasibility of engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices already in clinical use, for improved tumour uptake and therapeutic outcome. The Programme Grant will enable the creation of a sustainable, world-unique multi-disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a unique training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice.
A unique feature of the Centre is the capability to design both devices and drug delivery vehicles under a single roof. In the first 5 years, under EPSRC funding, up to 3 carefully selected "Device+Drug" exemplars will be manufactured to GMP, ready for Phase I clinical trials, to provide compelling evidence of feasibility to industrial partners and clinicians; in the next 5 years, a private-public partnership will be built to complete clinical trials of these exemplars using therapeutics of strategic significance to the pharmaceutical industry; beyond 10 years, full industrial sponsorship of the OXCD3 is anticipated, which will focus on addressing next-generation challenges in drug delivery (beyond cancer) in partnership with industry and clinicians. The transformative aim over 50 years is to position the UK as the world leader for multi-disciplinary drug delivery development, complementing its existing position as a drug discovery leader, from design to manufacture and clinical trials.
Planned Impact
The proposed programme grant spans two of EPSRC's core strategic areas, "Healthcare Technologies" and "Manufacturing the Future" and will be key in providing the UK with a world-leading position in the exploding fields of targeted drug delivery and nanotechnology biomanufacturing. In addition to academic excellence in addressing the greatest challenge in oncological drug delivery (achieving tumour penetration), its aim is to provide the underlying science and manufacturing know-how that will enable successful delivery of existing and future anti-cancer agents, transforming both UK healthcare and UK industry.
True impact in biomedical engineering and drug delivery is achieved in one of three, often interlinked ways: translation from bench to bedside through clinical trials and demonstration of therapeutic efficacy; dissemination of transformative science and techniques through high-impact peer-reviewed publications for uptake by the academic and industrial communities; and commercialization of new advances, either through licensing to existing manufacturers or through the formation of new spin-out companies.
The impact of major advances in drug delivery has historically been limited by three factors:
(i) Scale-up: most innovative drug carrier manufacturing techniques developed in the laboratory are poorly suited to large-scale manufacturing, and often overlook the constraints of manufacturing to GMP as needed for clinical trials, thus requiring major and costly redevelopment before clinical trials and uptake by industry.
The OXCD3 difference: Involve the Clinical Biomanufacturing Facility from day one, so that laboratory techniques are selected from an early stage to be compatible with GMP scale-up.
(ii) Non-anticipation of regulatory hurdles, particularly for complex combinational products: the choice of drug vehicle materials and of the type of excitation required for device-triggered release will greatly affect the cost and complexity of experimentation and biocompatibility studies required for regulatory approval to enter the clinic.
The OXCD3 difference: Involve clinicians and a qualified pharmacist (QP) with direct experience of managing drug, device and combinational trials from day one,
(iii) Excessively long timescale to first-in-man trials:
The OXCD3 difference: Deliver not only transformative science but also three exemplars already manufactured to GMP ready for a clinical trial by the end of the funding period.
True impact in biomedical engineering and drug delivery is achieved in one of three, often interlinked ways: translation from bench to bedside through clinical trials and demonstration of therapeutic efficacy; dissemination of transformative science and techniques through high-impact peer-reviewed publications for uptake by the academic and industrial communities; and commercialization of new advances, either through licensing to existing manufacturers or through the formation of new spin-out companies.
The impact of major advances in drug delivery has historically been limited by three factors:
(i) Scale-up: most innovative drug carrier manufacturing techniques developed in the laboratory are poorly suited to large-scale manufacturing, and often overlook the constraints of manufacturing to GMP as needed for clinical trials, thus requiring major and costly redevelopment before clinical trials and uptake by industry.
The OXCD3 difference: Involve the Clinical Biomanufacturing Facility from day one, so that laboratory techniques are selected from an early stage to be compatible with GMP scale-up.
(ii) Non-anticipation of regulatory hurdles, particularly for complex combinational products: the choice of drug vehicle materials and of the type of excitation required for device-triggered release will greatly affect the cost and complexity of experimentation and biocompatibility studies required for regulatory approval to enter the clinic.
The OXCD3 difference: Involve clinicians and a qualified pharmacist (QP) with direct experience of managing drug, device and combinational trials from day one,
(iii) Excessively long timescale to first-in-man trials:
The OXCD3 difference: Deliver not only transformative science but also three exemplars already manufactured to GMP ready for a clinical trial by the end of the funding period.
Organisations
- University of Oxford (Lead Research Organisation)
- University of Twente (Collaboration)
- AstraZeneca (Collaboration)
- National Institutes of Health (NIH) (Collaboration)
- Lein Applied Diagnostics (United Kingdom) (Project Partner)
- Cell Therapy (Project Partner)
- Verasonics Inc (Project Partner)
- AstraZeneca (United Kingdom) (Project Partner)
- PsiOxus Therapeutics (United Kingdom) (Project Partner)
- Pfizer (United Kingdom) (Project Partner)
- Oxford Instruments (United Kingdom) (Project Partner)
- OrganOx (United Kingdom) (Project Partner)
- Karl Storz (Germany) (Project Partner)
Publications
Haemmerich D
(2018)
Non-invasive image-guided targeted drug delivery.
in The Lancet. Oncology
Hettinga J
(2020)
Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects.
in Vaccines
Hettinga J
(2023)
Cavitation-Mediated Transcutaneous Delivery of Protein and Nucleotide-based Antigen for Rapid High-level Immune Responses
in Advanced Therapeutics
Hill C
(2019)
Achieving systemic delivery of oncolytic viruses.
in Expert opinion on drug delivery
Hill C
(2021)
Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.
in Molecular therapy oncolytics
Jarrett D
(2019)
Applications and limitations of machine learning in radiation oncology.
in The British journal of radiology
Kazmi F
(2020)
Megavoltage Radiosensitization of Gold Nanoparticles on a Glioblastoma Cancer Cell Line Using a Clinical Platform.
in International journal of molecular sciences
Kooiman K
(2020)
Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery.
in Ultrasound in medicine & biology
Kwan J
(2016)
Ultrahigh-Speed Dynamics of Micrometer-Scale Inertial Cavitation from Nanoparticles
in Physical Review Applied
Description | The Oxford Centre for Drug Delivery Devices (OxCD3) launched on the 23rd July 2014 to address one of the greatest challenges in oncology: achieving successful penetration and distribution of the therapeutic agent throughout the tumour. The Centre's research spans 4 work packages (WPs), each led by at least one physical and one medical investigator, and resourced with two post-doctoral fellows and 2-3 doctoral (DPhil) students. o WP1 (Coussios, Seymour, Carlisle) exploits cavitating nanoparticles for ultrasound-enhanced delivery of biologics. o WP2 (Carlisle, Vallis) develops liposomal encapsulation technologies for ultrasound-enhanced delivery of radiopharmaceuticals. o WP3 (Cleveland, Rabbitts) investigates the use of shock waves for delivery across the cell membrane. o WP4 (Stride, Sibson) is concerned with combining magnetic and ultrasound approaches for brain theranostics. |
Exploitation Route | Active collaborations under CDAs and MTAs with pharma partners (GSK, Medimmune, AstraZeneca) to identify how to take these advances into the clinic over the next 3 years |
Sectors | Healthcare Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
URL | http://www.drugdelivery.org |
Description | The award enabled the development of novel methods for cavitation-enhanced oncological drug delivery, being commercially exploited by University spin-out OxSonics Ltd. In 2021, the University and OxSonics received a Product Development Award from the National Institute for Health Research to enable a first-in-human trial of cavitation-enhanced drug delivery in patients with metastatic colorectal cancer in the liver. By December 2023, the first 9 patients had been successfully treated as part of this trial, enabling the completion of the Safety Cohort with no safety concerns. By December 2024, 13 out the projected 36 patients had been successfully recruited and treated, providing compelling early evidence of the performance and efficacy of cavitation-enhanced drug delivery to improve therapeutic outcomes for metastatic colorectal cancer patients. The final set of patients will have been recruited by December 2024. |
First Year Of Impact | 2024 |
Sector | Healthcare |
Impact Types | Economic |
Description | Invitation to discuss Secretary of Business, Energy and Industry Strategy how government can support growth of biomedical engineering businesses |
Geographic Reach | National |
Policy Influence Type | Contribution to a national consultation/review |
Description | Bloodwise (formerly known as Leukaemia & Lymphoma Research) |
Amount | £1,400,000 (GBP) |
Organisation | Bloodwise |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2013 |
End | 02/2019 |
Description | CRUK Pioneer Award |
Amount | £200,000 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2016 |
End | 06/2018 |
Description | Chromosomal translocation genes and their protein interactions in cancer |
Amount | £2,223,000 (GBP) |
Funding ID | MR/J000612/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | EPSRC Responsive Mode |
Amount | £1,100,000 (GBP) |
Funding ID | EP/R013624/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2018 |
End | 07/2021 |
Description | Fast 3D Super-Resolution Ultrasound Imaging Through Acoustic Activation and Deactivation of Nanodroplets |
Amount | £331,377 (GBP) |
Funding ID | EP/T008067/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 06/2020 |
End | 06/2023 |
Description | Marie Sklodowska-Curie Individual Fellowship |
Amount | € 184,000 (EUR) |
Funding ID | 654985 |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 03/2015 |
End | 03/2017 |
Description | NIH - OXCAM scholarship |
Amount | $200,000 (USD) |
Organisation | National Institutes of Health (NIH) |
Sector | Public |
Country | United States |
Start | 08/2019 |
End | 08/2021 |
Description | Pancreatic Cancer Research Fund |
Amount | £180,000 (GBP) |
Organisation | Pancreatic Cancer Action (PCA) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2017 |
End | 06/2019 |
Description | Rosalind Franklin Institute |
Amount | £3,500,000 (GBP) |
Organisation | Research Complex at Harwell |
Sector | Public |
Country | United Kingdom |
Start | 03/2019 |
End | 02/2023 |
Description | Royal Commission for the Exhibition of 1851 - industrial fellowship |
Amount | £120,000 (GBP) |
Organisation | Royal Commission for the Exhibition of 1851 |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 09/2018 |
End | 09/2021 |
Description | Seeding Drug Development Award |
Amount | £3,825,714 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2012 |
End | 02/2017 |
Description | Wellcome Trust SI Award |
Amount | £2,345,550 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 03/2012 |
End | 02/2020 |
Title | Thermosensitive liposomes: a promising step toward localised chemotherapy |
Description | Many small molecules and biologic therapeutics have been developed for solid tumor therapy. However, the unique physiology of tumors makes the actual delivery of these drugs into the tumor mass inefficient. Such delivery requires transport from blood vessels, across the vasculature and into and through interstitial space within a tumor. This transportation is dependent on the physiochemical properties of the therapeutic agent and the biological properties of the tumor. It was hoped the application of nanoscale drug carrier systems would solve this problem. However, issues with poor tumor accumulation and limited drug release have impeded clinical impact. In response, these carrier systems have been redesigned to be paired with targetable external mechanical stimuli which can trigger much enhanced drug release and deposition. The pre-clinical and clinical progress of thermolabile drug carrier systems and the modalities used to trigger the release of their cargo are assessed. Combined application of mild hyperthermia and heat-responsive liposomal drug carriers has great potential utility. Clinical trials continue to progress this approach and serve to refine the technologies, dosing regimens and exposure parameters that will provide optimal patient benefit. |
Type Of Material | Database/Collection of data |
Year Produced | 2022 |
Provided To Others? | Yes |
URL | https://tandf.figshare.com/articles/dataset/Thermosensitive_liposomes_a_promising_step_toward_locali... |
Title | Thermosensitive liposomes: a promising step toward localised chemotherapy |
Description | Many small molecules and biologic therapeutics have been developed for solid tumor therapy. However, the unique physiology of tumors makes the actual delivery of these drugs into the tumor mass inefficient. Such delivery requires transport from blood vessels, across the vasculature and into and through interstitial space within a tumor. This transportation is dependent on the physiochemical properties of the therapeutic agent and the biological properties of the tumor. It was hoped the application of nanoscale drug carrier systems would solve this problem. However, issues with poor tumor accumulation and limited drug release have impeded clinical impact. In response, these carrier systems have been redesigned to be paired with targetable external mechanical stimuli which can trigger much enhanced drug release and deposition. The pre-clinical and clinical progress of thermolabile drug carrier systems and the modalities used to trigger the release of their cargo are assessed. Combined application of mild hyperthermia and heat-responsive liposomal drug carriers has great potential utility. Clinical trials continue to progress this approach and serve to refine the technologies, dosing regimens and exposure parameters that will provide optimal patient benefit. |
Type Of Material | Database/Collection of data |
Year Produced | 2022 |
Provided To Others? | Yes |
URL | https://tandf.figshare.com/articles/dataset/Thermosensitive_liposomes_a_promising_step_toward_locali... |
Description | Delivery of liposomal mRNA |
Organisation | AstraZeneca |
Department | Research and Development AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have identified novel methods of delivering liposomal mRNA to cells using shock waves and ultrasound |
Collaborator Contribution | We have been provided with a proprietary mRNA liposomal formulation and expertise on how to quantify mRNA delivery. |
Impact | There are no published outputs yet. |
Start Year | 2016 |
Description | High-speed imaging of ultrasound-enhanced drug delivery and associated mechnanisms |
Organisation | University of Twente |
Department | Physics of Fluids |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | We have designed, manufactured and supplied novel vehicles for ultrasound-mediated drug delivery, expertise in real-time cavitation detection, and a member of staff for up to 10 weeks to help conduct experiments in Twente. |
Collaborator Contribution | Access to a world-unique ultra-high-speed camera (Brandaris) and access for up 10 weeks to an expert researcher to setup and conduct the experiments. |
Impact | In vitro methods to study bubble-cell interactions: Fundamentals and therapeutic applications. G Lajoinie, I De Cock, CC Coussios, I Lentacker, S Le Gac, E Stride, M Versluis Biomicrofluidics 10 (1), 011501 (2016) |
Start Year | 2014 |
Description | Ultrasound-enhanced immuno-oncology |
Organisation | National Institutes of Health (NIH) |
Country | United States |
Sector | Public |
PI Contribution | We have contributed expertise in the generation and mapping of intratumoural cavitation to enhance the delivery and distribution of therapeutic antibodies. |
Collaborator Contribution | The NIH provided an outstanding NIH OxCam Fellow with expertise in immuno-oncology who completed his DPhil at the University of Oxford on the topic of cavitation-enhanced delivery and efficacy of checkpoint inhibitors. |
Impact | Multi-disciplinary collaboration involving biomedical engineering, acoustics, signal processing, immunology, pharmacology and oncology |
Start Year | 2016 |
Description | University of Twente |
Organisation | University of Twente |
Department | Developmental BioEngineering (Twente) |
Country | Netherlands |
Sector | Hospitals |
PI Contribution | my team has provided materials and expertise for the fabrication of drug loaded microbubbles and nanoparticles for initiating cavitation as well as microfluidic systems |
Collaborator Contribution | The University of Twente has provided us with access to their unique high speed imaging facility to study various phenomena related to ultrasound mediated cavitation. They have hosted several of our researchers over a series of visits. |
Impact | V. Pereno, M. Aron, O.Vince, C. Mannaris, A. Seth, M. de Saint Victor, G. Lajoinie, M. Versluis, C. Coussios, D. Carugo, E. Stride. Layered acoustofluidic resonators for the study of the physical and biological effects of acoustic cavitation. Biomicrofluidics 12: 034109 (2018) G. Lajoinie, J. Lee, P. Kruizinga, J. Owen, G. van Soest, N. de Jong, E. Stride and M. Versluis. Laser driven resonance of microbubbles: experimental study. J. Acoust. Soc. Am. 141: 4832-4846 (2017) G. Lajoinie, E. Linnartz, P. Kruizinga, G. van Soest, E. Stride and M. Versluis. Laser driven dynamics of optically absorbing microbubbles: a theoretical and numerical study. J. Acoust. Soc. Am. 141 (4), 2727-2745 (2017) J. Kwan, G. Lajoinie, N. de Jong, E. Stride, M. Versluis, C. Coussios. Ultra High Speed Dynamics of Micron- Sized Inertial Cavitation from Nanoparticles. Physical Review Applied 6:044004 (2016). J. Kwan, G. LaJoinie, E., M. Versluis, and Constantin Coussios. Bubble dynamics of inertial cavitation from nanoparticles. The 14th International Symposium on Therapeutic Ultrasound, Utrecht, The Netherlands 15th-18th April 2015 all interdisciplinary: Engineering, Physics, Oncology, Imaging |
Start Year | 2015 |
Title | MAGNETO-ACOUSTIC DEVICE |
Description | A device for magnetic drug targeting, comprising: a magnetic element (3) for providing a magnetic field configured to retain magnetic microbubbles within a target volume; an ultrasound element (2) for providing an acoustic field configured to excite the magnetic microbubbles while the magnetic microbubbles are retained by the magnetic field within the target volume. |
IP Reference | US2020282055 |
Protection | Patent application published |
Year Protection Granted | 2020 |
Licensed | No |
Impact | The authors have been approached by a healthcare venture company and formation of a spin out company is under discussion |
Title | TarDox |
Description | Non-invasive targeted doxorubicin delivery from thermosensitive liposomes using high-intensity focussed ultrasound in cancer patients with metastases to the liver. This is a first-in-man trial enabled by the work carried out under my Challenging Engineering award and supported by the Oxford Centre for Drug Delivery Devices (OxCD3) and the Oxford BRC (NIHR) . |
Type | Therapeutic Intervention - Drug |
Current Stage Of Development | Early clinical assessment |
Year Development Stage Completed | 2014 |
Development Status | Under active development/distribution |
Clinical Trial? | Yes |
Impact | Ten patients were successfully treated between 2016 and 2018 and the outputs of the trial were reported in Lancet Oncology (2018) and Radiology (2019) |
URL | https://clinicaltrials.gov/ct2/show/NCT02181075 |
Company Name | OxSonics |
Description | OxSonics has developed ultrasound technology to deliver drugs to treat cancers and chronic lower back pain. |
Year Established | 2013 |
Impact | The company received a £2.5m Innovate UK early stage award in 2014 to enable pre-clinical development of the ultrasound device, associated ultrasound transducer and GMP manufacture of the sonosensitive particles. |
Website | http://www.oxsonics.com |
Description | Expert comment for BBC news; press release on focused ultrasound blood-brain barrier (BBB) opening (Nov 2015) |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | I was asked to provide an expert opinion on recent findings from a group in the United States in which they demonstrated focussed opening of the blood-brain barrier in primary brain tumours. |
Year(s) Of Engagement Activity | 2015 |
Description | Gresham College Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Public lecture for Gresham college with ~50 attendees in person and over 200 online for the live broadcast. The talk was followed by a lively Q& A session |
Year(s) Of Engagement Activity | 2022 |
URL | https://www.gresham.ac.uk/lectures-and-events/cancer-therapy |
Description | Inclusive Healthcare Webinar |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Online panel discussion about initiatives to improve inclusivity in healthcare attended by representatives of the pharmaceutical industry, patients, clinicians, academics and charitable foundations, with a large online audience and recording available post-broadcast. |
Year(s) Of Engagement Activity | 2022 |
URL | https://nooneleftbehind.co.uk/resources |
Description | International Society for Therapeutic Ultrasound - Tutorial Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Over 200 people logged into listen to the lecture which was followed by a live question and answer session and subsequent engagement by email. Excellent feedback was received from the audience including a proposal for a research collaboration. |
Year(s) Of Engagement Activity | 2021 |
URL | https://istu.org/february-25-2021-webinar/ |
Description | MRC Festival of Medical Research |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Other audiences |
Results and Impact | The MRC festival is a one week travel around public spaces in towns around Oxford. The idea is to reach out to people who live too far away to come to us. And to put ourselves in the way of people who might not come to a science event - we're setting up shop in supermarkets, shopping centres and markets. It was very successful last year with nearly 1000 people talking to us over the week. |
Year(s) Of Engagement Activity | 2017 |
Description | MSc and DTC Lectures |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Type Of Presentation | Keynote/Invited Speaker |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Regular lectures on brain imaging in cancer and neurosciences to Doctoral Training Course and M.Sc. students, which sparked questions and discussion as well as interest in entering research within this field of research. Outcome is often one or more students joining the group for either M.Sc. or D.Phil. projects. Development of collaborations and numerous examples of interest in applying our VCAM-targeted technology in different patients groups from paediatrics to head injury. |
Year(s) Of Engagement Activity | 2009,2010,2011,2012,2013,2014,2015,2016 |
Description | Manchester Literary and Philosophical Society |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Public lecture organised by the Manchester Literary and Philosophical Society; attended by ~50 people with an online audience as well (size unknown). Lively Q&A session followed the talk and subsequent email communication with further questions. |
Year(s) Of Engagement Activity | 2021 |
URL | https://www.manlitphil.ac.uk/resources/autumn-2021-programme |
Description | Mercedes Family Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Manned a stall at the Mercedes family day for CRUK, explaining aspects of cancer research within the Institute. Lots of people participated and were very engaged and interested in the research being done. |
Year(s) Of Engagement Activity | 2017 |
Description | STEM Potential Women in Science Webinar |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | Online panel discussion of female scientists with an audience of university students (post and undergraduate). Feedback following the session indicate students had found the session very helpful and it had positively influenced their career choices. |
Year(s) Of Engagement Activity | 2021 |
URL | https://youtu.be/oXk8RUSVpZg |
Description | Staff talk for CRUK at Mercedes-Benz Grand Prix |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Public/other audiences |
Results and Impact | Presentation of CRUK funded work at Mercedes-Benz as CRUK is their nominated charity. Many of the audience (approx 100) found resonance with the topic (brain cancer) and commented afterwards that they were interested and excited to hear what research is being done. |
Year(s) Of Engagement Activity | 2017 |
Description | Super Science Saturday |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Public/other audiences |
Results and Impact | Public engagement event at the Natural History Museum in Oxford - 2 postdocs participated in sharing our research with the public. |
Year(s) Of Engagement Activity | 2017 |
Description | Talk at Founders Forum |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | The talk was supposed to raise awareness about the role of engineering approaches in healthcare, specifically cancer treatment. It has generated significant media interest and contacts from industrial and medical practitioners. |
Year(s) Of Engagement Activity | 2018 |
URL | https://www.havaslynx.com/founders-forum-health-tech-2018/ |